A study evaluating the safety and efficacy of Polatuzumab vedotin in combination with Rituximab plus Gemcitabine plus Oxaliplatin (R-GEMOX) versus R-GEMOX alone in relapsed/refractory Diffuse Large B Cell Lymphoma (MO40598)
A study evaluating the safety and efficacy of Polatuzumab vedotin in combination with Rituximab plus Gemcitabine plus Oxaliplatin (R-GEMOX) versus R-GEMOX alone in relapsed/refractory Diffuse Large B Cell Lymphoma (MO40598)
Trial Category:
Lymphoma
Phase
III
Contact(s)
Location(s)
Nebraska Cancer Specialists, Omaha, NE
